Skip to content

A Two-Way Nested Case-Control Study on the Diagnosis of Sensitivity to Neoadjuvant Chemotherapy Combined with Immunotherapy in Advanced Gastric Cancer Based on Proteomics/Phosphoproteomics

A Two-Way Nested Case-Control Study on the Diagnosis of Sensitivity to Neoadjuvant Chemotherapy Combined with Immunotherapy in Advanced Gastric Cancer Based on Proteomics/Phosphoproteomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120271
Enrollment
Unknown
Registered
2026-03-11
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Observation group:None

Sponsors

Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1.Age >= 18 years, gender unrestricted. 2. Pathologically confirmed gastric adenocarcinoma via gastroscopic biopsy, staged as TNM Stage ?–? per the 8th edition of the AJCC Gastric Cancer Staging System. 3. Scheduled to receive neoadjuvant chemotherapy combined with immunotherapy (chemotherapy regimens: SOX/XELOX; immunotherapy: PD-1 inhibitor), with no prior antitumor treatment (including chemotherapy, radiotherapy, immunotherapy, etc.). 4.Estimated survival time >= 6 months and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0–1. 5.Willing to enroll, sign the Informed Consent Form (ICF), and commit to completing 3-month follow-up and sample collection as required.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1.Concomitant other active malignancies, or severe cardio-cerebrovascular diseases (e.g., myocardial infarction within the past 6 months, uncontrolled hypertension/uncontrolled diabetes mellitus). 2.History of autoimmune disease, active infection (e.g., active HBV/HCV infection, HIV-positive status), or immunodeficiency. 3.Hypersensitivity to components of chemotherapeutic agents (e.g., oxaliplatin, tegafur–gimeracil–oteracil potassium) or immune checkpoint inhibitors. 4.Administration of immunomodulators (e.g., systemic glucocorticoids at a prednisone-equivalent dose > 10 mg/day) within 3 months prior to enrollment. 5.Unable to comply with sample collection (e.g., contraindications to gastroscopic biopsy) or follow-up (e.g., cognitive impairment).

Design outcomes

Primary

MeasureTime frame
Treatment Sensitivity;

Secondary

MeasureTime frame
Overall Survival (OS);

Countries

China

Contacts

Public ContactFang Yuan

Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine/Shanghai General Hospital

fangyuan1231@aliyun.com+86 139 1812 1439

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026